Physician profile
Eric Loman
NPI 1952662140
$4,339.56
in general payments reported to CMS, 2019-2025
26 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $267 · 2021: $865 · 2022: $736 · 2023: $442 · 2024: $649 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843 · Education: $56.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.62 |
| Education | $56.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,545.64 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $493.10 | 2019-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $383.47 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $272.10 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $177.95 | 2024-2025 | Rayaldee |
| Travere Therapeutics, INC. | $167.49 | 2023-2025 | Filspari |
| Ardelyx, INC. | $146.21 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Davol INC. | $140.41 | 2021 | |
| Horizon Therapeutics Plc | $126.75 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $105.52 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $94.82 | 2022-2025 | Terlivaz |
| Novo Nordisk INC | $91.35 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $88.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $86.73 | 2019-2020 | |
| Amgen INC. | $62.75 | 2024-2025 | Krystexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $56.27 | 2022-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $49.38 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $42.63 | 2019-2023 | Injectafer |
| Scpharmaceuticals INC. | $37.94 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.12 | 2024-2025 | Jardiance |
| Bard Peripheral Vascular, INC. | $30.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.92 | 2024-2025 | Eohilia |
| Fresenius USA Marketing, INC. | $25.65 | 2019 | |
| Shire North American Group INC | $22.99 | 2019 | |
| Akebia Therapeutics INC | $19.00 | 2025 | Vafseo |
| Lundbeck LLC | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Loman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.